Will TL1A be the gateway to precision medicine in inflammation?

TL1A inhibitors appear poised to usher precision medicine into large inflammatory and autoimmune indications, but whether the field’s leading companies will ultimately view their biomarkers as opportunities for differentiation or a burden that limits the market remains to be seen. Hanging in the balance is the benefit patients would receive from access to a diagnostic that could tell them their chances of responding.

Therapeutic mechanisms that fit the precision medicine model in inflammatory diseases are rare. So far, none have made it to the market. TL1A inhibitors in development for inflammatory bowel disease (IBD) could be the first...